|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/30/21 Allscripts Healthcare Soluti… Inc 10-Q 3/31/21 101:13M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.10M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
11: R1 Document and Entity Information HTML 83K
12: R2 Consolidated Balance Sheets (Unaudited) HTML 141K
13: R3 Consolidated Balance Sheets (Unaudited) HTML 56K
(Parenthetical)
14: R4 Consolidated Statements of Operations (Unaudited) HTML 144K
15: R5 Consolidated Statements of Comprehensive Income HTML 60K
(Loss) (Unaudited)
16: R6 Consolidated Statements of Stockholders' Equity HTML 93K
(Unaudited)
17: R7 Consolidated Statements of Cash Flows (Unaudited) HTML 133K
18: R8 Consolidated Statements of Cash Flows HTML 30K
(Parenthetical) (Unaudited)
19: R9 Basis of Presentation and Significant Accounting HTML 38K
Policies
20: R10 Revenue from Contracts with Customers HTML 150K
21: R11 Accounts Receivables HTML 45K
22: R12 Leases HTML 104K
23: R13 Business Combinations and Divestitures HTML 35K
24: R14 Fair Value Measurements and Long-term Investments HTML 200K
25: R15 Stockholders' Equity HTML 93K
26: R16 Earnings (Loss) Per Share HTML 125K
27: R17 Goodwill and Intangible Assets HTML 161K
28: R18 Debt HTML 152K
29: R19 Income Taxes HTML 51K
30: R20 Derivative Financial Instruments HTML 102K
31: R21 Accumulated Other Comprehensive Loss HTML 170K
32: R22 Contingencies HTML 36K
33: R23 Discontinued Operations HTML 125K
34: R24 Business Segments HTML 99K
35: R25 Supplemental Disclosures HTML 50K
36: R26 Basis of Presentation and Significant Accounting HTML 52K
Policies (Policies)
37: R27 Revenue from Contracts with Customers (Tables) HTML 143K
38: R28 Accounts Receivables (Tables) HTML 44K
39: R29 Leases (Tables) HTML 106K
40: R30 Fair Value Measurements and Long-term Investments HTML 201K
(Tables)
41: R31 Stockholders' Equity (Tables) HTML 86K
42: R32 Earnings (Loss) Per Share (Tables) HTML 126K
43: R33 Goodwill and Intangible Assets (Tables) HTML 163K
44: R34 Debt (Tables) HTML 153K
45: R35 Income Taxes (Tables) HTML 45K
46: R36 Derivative Financial Instruments (Tables) HTML 103K
47: R37 Accumulated Other Comprehensive Loss (Tables) HTML 171K
48: R38 Discontinued Operations (Tables) HTML 127K
49: R39 Business Segments (Tables) HTML 94K
50: R40 Supplemental Disclosures (Tables) HTML 49K
51: R41 Basis of Presentation and Significant Accounting HTML 46K
Policies - Additional Information (Detail)
52: R42 Revenue from Contracts with Customers - Additional HTML 61K
Information (Detail)
53: R43 Revenue from Contracts with Customers - Summary of HTML 42K
Revenue Recognized on Various Performance
Obligations and Elected Accounting Expedients
(Detail)
54: R44 Revenue from Contracts with Customers - Summary of HTML 56K
Revenue by Type and Nature of Revenue Stream by
Reportable Segments (Detail)
55: R45 Revenue from Contracts with Customers - Summary of HTML 39K
Changes in Estimate of Credit Losses for Contract
Assets (Detail)
56: R46 Accounts Receivables - Additional Information HTML 35K
(Detail)
57: R47 Accounts Receivables - Schedule of Changes in HTML 39K
Estimate of Credit Losses for Trade Accounts
Receivable (Detail)
58: R48 Leases - Additional Information (Detail) HTML 36K
59: R49 Leases - Summary of Operating Costs Associated HTML 36K
with Leased Assets (Detail)
60: R50 Leases - Supplemental Cash Flow Information for HTML 33K
Operating Leases (Detail)
61: R51 Leases - Summary of Balance Sheet Location and HTML 39K
Balances for Operating Leases (Detail)
62: R52 Leases - Summary of Future Maturities of Lease and HTML 50K
Non-Lease Components (Detail)
63: R53 Business Combinations and Divestitures - HTML 67K
Additional Information (Detail)
64: R54 Fair Value Measurements and Long-term Investments HTML 57K
- Summary of Financial Assets and Liabilities
Measured at Fair Value on Recurring Basis (Detail)
65: R55 Fair Value Measurements and Long-term Investments HTML 35K
- Summary of Changes in Liability Measured at Fair
Value on Recurring Basis (Detail)
66: R56 Fair Value Measurements and Long-term Investments HTML 57K
- Summary of Quantitative Information About Fair
Value Measurements (Detail)
67: R57 Fair Value Measurements and Long-term Investments HTML 47K
- Summary of Long-term Equity Investments Included
in Other Assets (Detail)
68: R58 Fair Value Measurements and Long-term Investments HTML 30K
- Additional Information (Detail)
69: R59 Stockholders' Equity - Additional Information HTML 62K
(Detail)
70: R60 Stockholders' Equity - Stock-Based Compensation HTML 43K
Expense (Detail)
71: R61 Stockholders' Equity - Stock-Based Awards Granted HTML 42K
(Detail)
72: R62 Earnings (Loss) Per Share - Calculations of HTML 89K
Earnings (Loss) Per Share (Detail)
73: R63 Earnings (Loss) Per Share - Anti-Dilutive Stock HTML 31K
Options, Restricted Stock Unit Awards and Warrants
Excluded from Computation of Diluted Earnings
(Loss) Per Share (Detail)
74: R64 Goodwill and Intangible Assets - Goodwill and HTML 48K
Intangible Assets (Detail)
75: R65 Goodwill and Intangible Assets - Changes in HTML 40K
Carrying Amount of Goodwill (Detail)
76: R66 Goodwill and Intangible Assets - Additional HTML 31K
Information (Detail)
77: R67 Debt - Debt Outstanding Excluding Lease HTML 41K
Obligations (Detail)
78: R68 Debt - Debt Outstanding Excluding Lease HTML 40K
Obligations (Parenthetical) (Detail)
79: R69 Debt - Interest Expense (Detail) HTML 38K
80: R70 Debt - Interest Expense Related to 0.875% HTML 37K
Convertible Senior Notes and 1.25% Cash
Convertible Senior Notes (Detail)
81: R71 Debt - Additional Information (Detail) HTML 117K
82: R72 Debt - Summary of Future Debt Payment Obligations HTML 49K
(Detail)
83: R73 Effective Tax Rates (Detail) HTML 39K
84: R74 Income Taxes - Additional Information (Detail) HTML 42K
85: R75 Derivative Financial Instruments - Fair Value and HTML 36K
Balance Sheet Locations - (Detail)
86: R76 Derivative Financial Instruments - Additional HTML 44K
Information (Detail)
87: R77 Derivative Financial Instruments - Derivatives HTML 43K
Instruments Designated as Cash Flow Hedges -
(Detail)
88: R78 Accumulated Other Comprehensive Loss - Components HTML 56K
of Accumulated Other Comprehensive Loss (Detail)
89: R79 Accumulated Other Comprehensive Loss - Components HTML 34K
of Accumulated Other Comprehensive Loss
(Parenthetical) (Detail)
90: R80 Accumulated Other Comprehensive Loss - Income Tax HTML 78K
Effects Related to Components of Other
Comprehensive Income (Loss) (Detail)
91: R81 Contingencies - Additional Information (Detail) HTML 40K
92: R82 Discontinued Operations - Additional Information HTML 30K
(Detail)
93: R83 Discontinued Operations - Summary of Major Classes HTML 42K
of Assets and Liabilities as Reported on
Consolidated Balance Sheets (Detail)
94: R84 Discontinued Operations - Summary of Major Income HTML 79K
and Expense Line Items Reported in Consolidated
Statements of Operations (Detail)
95: R85 Business Segments - Additional Information HTML 31K
(Detail)
96: R86 Business Segments - Revenues and Income (Loss) HTML 51K
from Operations Related to Segment Within
Reconciliation to Consolidated Amounts (Detail)
97: R87 Supplemental Disclosures - Supplemental HTML 37K
Disclosures (Detail)
99: XML IDEA XML File -- Filing Summary XML 195K
10: XML XBRL Instance -- mdrx-10q_20210331_htm XML 3.48M
98: EXCEL IDEA Workbook of Financial Reports XLSX 115K
6: EX-101.CAL XBRL Calculations -- mdrx-20210331_cal XML 281K
7: EX-101.DEF XBRL Definitions -- mdrx-20210331_def XML 771K
8: EX-101.LAB XBRL Labels -- mdrx-20210331_lab XML 1.46M
9: EX-101.PRE XBRL Presentations -- mdrx-20210331_pre XML 1.21M
5: EX-101.SCH XBRL Schema -- mdrx-20210331 XSD 215K
100: JSON XBRL Instance as JSON Data -- MetaLinks 466± 732K
101: ZIP XBRL Zipped Folder -- 0001564590-21-022512-xbrl Zip 226K
Exhibit 31.2
Certification
I, Richard J. Poulton, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q of Allscripts Healthcare Solutions, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a. |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b. |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c. |
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d. |
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions): |
|
|
a. |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
|
b. |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: April 30, 2021 |
|
|
|
|
|
President and Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/30/21 | None on these Dates | ||
| For Period end: | 3/31/21 | |||
| List all Filings | ||||